Table 1 Baseline characteristics of participants
Before Lumacaftor/Ivacaftor treatment (N = 12) | Mean (SD) |
|---|---|
Age in years at start | 28.3 (± 6.9) |
Male/ Female | 8 (67%) / 4 (33%) |
CFRD at start | 4 (33%) |
ppFEV1% | 60 (± 16.9) |
ppFVC % | 75.5 (± 16.7) |
ppFEF25-75% | 30.1 (± 17.4) |
BMI Kg/m2 | 20.5 (± 3.4) |
Sweat chloride mEq/L a | 107.7 (± 11.6) |
CT Bhalla score b | 12.8 (± 2.7) |